Search results for "CLO"

showing 10 items of 9986 documents

Infections of susceptible and resistant mouse strains with herpes simplex virus type 1 and 2.

1980

The spread of HSV of type 1 and 2 was investigated after intraperitoneal, intraplantar and intracerebral infections of resistant (C57/bl) and susceptible (NMRI) mice. The virus spreads after i.p. infection to the spleen and the liver to the same extent in both strains of mice. However, virus is eliminated earlier in resistant mice. Intracerebral infections revealed a peculiar type of resistance of C57/bl mice especially for type 2 of HSV. HSV multiplies in the thymus at the early stage of infection and can be detected in this organ in sick mice of NMRI strain. HSV-1 and 2 can be detected in the spinal cord of C57/bl mice without sickness or death of these animals.

medicine.medical_specialtyanimal structuresvirusesSpleenHSL and HSVThymus GlandBiologymedicine.disease_causeVirusMiceMedical microbiologyImmunityVirologymedicineAnimalsSimplexvirusCyclophosphamidefungiBrainHerpes SimplexGeneral MedicineSpinal cordVirologyImmunity InnateMice Inbred C57BLHerpes simplex virusmedicine.anatomical_structureLiverSpinal CordInfectious disease (medical specialty)SpleenArchives of virology
researchProduct

Investigational agents for Crohn's disease.

2010

IMPORTANCE OF THE FIELD: Increased understanding of the biological mechanisms of Crohn's disease has opened the door to a large number of new molecules; some of these are approved for clinical use, while others remain under evaluation. In this review, we examine the clinical efficacy of all the new drugs that have been evaluated in controlled trials in the last 12 years. AREAS COVERED IN THIS REVIEW: Anti-TNF therapy has been reviewed briefly, given the many comprehensive reviews on this topic; attention is focused mainly on the other biological therapies. In assessing the clinical efficacy of these molecules, we consider only the remission rate, as this is considered the most meaningful en…

medicine.medical_specialtybiological therapy. Crohn' s disease. Integrins.Probiotics.Small molecules.DiseaseAdaptive ImmunityReceptors Tumor Necrosis FactorCrohn DiseaseGastrointestinal AgentsmedicineHumansImmunologic FactorsPharmacology (medical)Clinical efficacyIntensive care medicineRandomized Controlled Trials as TopicPharmacologyMitogen-Activated Protein Kinase KinasesBiological therapiesCrohn's diseaseEverolimusEnd pointINVESTIGATIONAL AGENTSbusiness.industryRemission InductionAntibodies MonoclonalGeneral MedicineDrugs Investigationalmedicine.diseaseImmunity InnateImmunologyCytokinesRemission rateImmunotherapybusinessCell Adhesion Moleculesmedicine.drugExpert opinion on investigational drugs
researchProduct

Secretagogues Modulate the Calcium Concentration in the Endoplasmic Reticulum of Insulin-secreting Cells

1999

The precise regulation of the Ca2+ concentration in the endoplasmic reticulum ([Ca2+]er) is important for protein processing and signal transduction. In the pancreatic beta-cell, dysregulation of [Ca2+]er may cause impaired insulin secretion. The Ca2+-sensitive photoprotein aequorin mutated to lower its Ca2+ affinity was stably expressed in the endoplasmic reticulum (ER) of rat insulinoma INS-1 cells. The steady state [Ca2+]er was 267 +/- 9 microM. Both the Ca2+-ATPase inhibitor cyclopiazonic acid and 4-chloro-m-cresol, an activator of ryanodine receptors, caused an almost complete emptying of ER Ca2+. The inositol 1,4,5-trisphosphate generating agonists, carbachol, and ATP, reduced [Ca2+]e…

medicine.medical_specialtybiologyRyanodine receptorEndoplasmic reticulumAequorinDepolarizationCell BiologyBiochemistryCell biologychemistry.chemical_compoundEndocrinologychemistryInternal medicinebiology.proteinmedicineInositolCyclopiazonic acidMolecular BiologyIon transporterHomeostasisJournal of Biological Chemistry
researchProduct

HEPATIC EXPRESSION OF CYCLOOXYGENASE-2 IN NON-ALCOHOLIC FATTY LIVER DISEASE

2008

medicine.medical_specialtybiologybusiness.industryFatty liverNon alcoholicDiseasemedicine.diseaseEndocrinologyInternal medicineInternal Medicinemedicinebiology.proteinCyclooxygenasebusinessEuropean Journal of Internal Medicine
researchProduct

<tocheading>Original Article</tocheading>

1999

In this double-blind clinical trial 429 patients (217 terbinafine and 212 clotrimazole) were randomized to receive twice daily terbinafine 1% topical solution for 1 week followed by a vehicle application for 3 weeks, or 1% clotrimazole solution for 4 weeks. Patients were evaluated clinically and mycologically at baseline and then at weeks one, two, four (end of treatment), and eight (end of follow-up). To be evaluable the patient needed to have a positive culture for a dermatophyte and positive KOH microscopy and a clinical diagnosis of tinea pedis (interdigital type) at baseline. Effective treatment of tinea pedis was recorded in 181 of 217 (83%) of patients treated for 1 week with terbina…

medicine.medical_specialtybusiness.industryClotrimazoleDermatologyGeneral Medicinemedicine.disease_causemedicine.diseaseDermatologylaw.inventionClinical trialInfectious DiseasesRandomized controlled trialTolerabilitylawmedicineDermatophyteTerbinafinebusinessAdverse effectMycosismedicine.drugMycoses
researchProduct

Nonsteroid Immunosuppressants in Endocrine Orbitopathy

2009

medicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismAziridinesEndocrine orbitopathyGeneral MedicineDermatologyGraves DiseaseEndocrinologyAzathioprineCyclosporineInternal MedicinemedicineHumansbusinessCyclophosphamideImmunosuppressive AgentsExperimental and Clinical Endocrinology & Diabetes
researchProduct

T-cell cloning in human type I diabetes.

1992

medicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismT-LymphocytesT lymphocyteHuman typemedicine.disease_causemedicine.diseaseBiochemistryAutoimmunityT cell cloningClone CellsEndocrinologyEndocrinologyDiabetes Mellitus Type 1Diabetes mellitusInternal medicineInsulin dependent diabetesImmunologymedicineHumansbusinessDiabetes/metabolism reviews
researchProduct

Clofarabine Significantly Increases Eradication of Minimal Residual Disease of B-Precursor ALL Compared to High-Dose Cytarabine in Randomized Trial C…

2020

Background Since the FDA approval of clofarabine for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) at childhood, several studies have been launched which put clofarabine under scrutiny in combination with other cytostatic drugs as second or third line therapy. As a novel treatment-strategy we introduced the combination of clofarabine with pegylated asparaginase (PEG-ASP) in a randomized fashion in comparison to the standard consolidation course with high dose cytarabine (Hidac) combined with PEG-ASP into the frontline management of ALL within the CoALL 08-09 protocol. The primary objective of the study was to compare the MRD based assessment of the cytotoxic eff…

medicine.medical_specialtybusiness.industryImmunologyUrologyCell BiologyHematologyBiochemistryMinimal residual diseaselaw.inventionHigh dose cytarabineRandomized controlled triallawmedicineClofarabinebusinessmedicine.drugBlood
researchProduct

0053: Incidence of cardiovascular events following myocardial infarction in France: an observational analysis using a claims database

2016

Objectives To describe the characteristics and treatments of patients having a myocardial infarction (MI) and estimate the incidence of cardiovascular events following the index MI, in the French Health Insurance database. Method A cohort of patients who had a MI in France between 2007 and 2011 was extracted from a claim database: the Echantillon Generaliste de Beneficiaires (a 1% representative sample of subjects covered by the general health insurance (?600,000 patients). The incidence of cardiovascular events following the index MI was estimated using the Kaplan Meier method. Results 1,977 subjects were identified with an index myocardial MI: 2/3 were males, mean age=67.2 y, 20.6% had di…

medicine.medical_specialtybusiness.industryIncidence (epidemiology)medicine.diseaseClopidogrelSurgeryDiabetes mellitusInternal medicineCohortmedicineCumulative incidenceMyocardial infarctionCardiology and Cardiovascular MedicinebusinessStrokeThiazidemedicine.drugArchives of Cardiovascular Diseases Supplements
researchProduct

Surgical Closure of Atrial and Ventricular Septal Defects

2010

medicine.medical_specialtybusiness.industryInternal medicineClosure (topology)medicineCardiologybusiness
researchProduct